Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : AbbVie Deutschland GmbH & Co. KG
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Post-liver or Post-kidney transplant with Chronic Hepatitis C Virus
The primary objectives of this study are to compare the 12-week sustained virologic response, SVR12 (HCV RNA < LLOQ 12 weeks following therapy) of 12 weeks of treatment with the ABT-493/ABT-530 combin...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A randomized, open-label, multicenter study comparing the efficacy, safety and tolerability of rovalpituzumab tesirine versus topotecan for DLL3high SCLC subjects with first relapse/recurrence following front-line platinum-based chemotherapy
The primary objective is to assess treatment with rovalpituzumab tesirine imrpoves objective response rate (ORR) and overall survival rate (OS) compared to topotecan in subjects with DLL3high SCLC who...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Phase 1 dose-finding and Phase 2 randomized double-blinded study evaluating if veliparib compared to placebo improves efficacy of caboplatin and etoposide combination in patients with untreated extensive stage small cell lung cancer
The Phase 1 primary objective is to establish the maximum tolerated dose and the recommended Phase 2 dose for veliparib in combination with carboplatin and etoposide in subjects with untreated extensi...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A study comparing the safety and efficacy of Adalimumab vs. Placebo in subjects with Inactive uveitis
The objective of this study is to evaluate the efficacy and safety of adalimumab 80 mg loading dose followed by 40 mg dose given every other week subcutaneously starting at Week 1 compared with placeb...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered with Daclatasvir in Adults with Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)
The primary objective of this study is to demonstrate non-inferiority in the percentage of subjects achieving a 12-week sustained virologic response (SVR12) of 12 weeks of treatment with ABT-493/ABT-5...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Efficacy and Safety of ABT-494 in Subjects With Moderately to Severely Active Ulcerative Colitis
Evaluate the efficacy and safety of ABT-494 in induction and maintenance of remission in subjects with moderately to severely active ulcerative colitis
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Study to Compare ABT-494 Monotherapy to Methotrexate Monotherapy in Subjects with Rheumatoid Arthritis (RA) Who have not Previously taken Methotrexate (SELECT-EARLY)
• To compare the safety and efficacy of ABT-494 monotherapy versus methotrexate (MTX) monotherapy for the treatment of signs and symptoms of rheumatoid arthritis (RA) in MTX-naïve subjects with modera...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A Study to Evaluate the Safety and Effect of Co-administration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection
The primary objective is to assess the safety and efficacy (the percentage of subjects with HCV RNA <LLOG 12 weeks after the last actual dose of study drug (SVR12 actual)) of ABT-450/r and ABT-267 amo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
Extension Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Subjects with Moderate to Severe Endometriosis-Associated Pain Estudio de extensión para evaluar la seguridad y la eficacia a largo plazo de elagolix en participantes con dolor de moderado a severo asociado a endometriosis
The primary objective of this 6-month extension study is to evaluate the continued safety, efficacy and tolerability of the 150 mg QD and 200 mg BID doses of elagolix (ABT-620) for up to 12 months in ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
AbbVie Deutschland GmbH & Co. KG
MAJ Il y a 5 ans
A study of subjects with Psoriatic Arthritis to investigate the effectiveness of adalimumab introduction compared with methotrexate dose escalation
To compare the effectiveness based on the achievement of minimal disease activity (MDA) at Week 16 between subjects who had adalimumab introduced and those that had methotrexate (MTX) escalated to the...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
2
3
4
5
6
7
8
9
10
11
Suivant